Vindesine, prednisone, and daunomycin in acute lymphoblastic leukemia in relapse. 1983

G Garay, and J Milone, and E Dibar, and S Pavlovsky, and R Kvicala, and F Sackmann Muriel, and D Montres Varela, and M Eppinger-Helft

Patients with resistant or recurrent acute lymphoblastic leukemia were treated with vindesine 3 mg/m2/IV weekly X 4, daunomycin 25 mg/m2/IV weekly X 4, and prednisone 40 mg/m2/PO daily X 28. Seventeen (44%) of 38 evaluable patients achieved complete remission. Fifty-one percent of 31 patients in first relapse achieved complete remission, while only one of five in second or third relapse and neither of two resistant to first induction achieved complete remission. The major toxicity was hematologic. The median duration of complete remission was only 6 weeks and median survival from start of the study, 3 months, with 22% patients remaining alive at 10 months. We conclude that the vindesine, prednisone, and daunomycin combination is no more effective than vincristine, prednisone, and daunomycin in achieving remission of relapsed acute lymphoblastic leukemia patients, and is more toxic than the latter regimen.

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

G Garay, and J Milone, and E Dibar, and S Pavlovsky, and R Kvicala, and F Sackmann Muriel, and D Montres Varela, and M Eppinger-Helft
March 1971, Cancer,
G Garay, and J Milone, and E Dibar, and S Pavlovsky, and R Kvicala, and F Sackmann Muriel, and D Montres Varela, and M Eppinger-Helft
August 1992, Investigational new drugs,
G Garay, and J Milone, and E Dibar, and S Pavlovsky, and R Kvicala, and F Sackmann Muriel, and D Montres Varela, and M Eppinger-Helft
May 1983, Cancer treatment reports,
G Garay, and J Milone, and E Dibar, and S Pavlovsky, and R Kvicala, and F Sackmann Muriel, and D Montres Varela, and M Eppinger-Helft
May 1983, Cancer treatment reports,
G Garay, and J Milone, and E Dibar, and S Pavlovsky, and R Kvicala, and F Sackmann Muriel, and D Montres Varela, and M Eppinger-Helft
January 2014, Chinese medical journal,
G Garay, and J Milone, and E Dibar, and S Pavlovsky, and R Kvicala, and F Sackmann Muriel, and D Montres Varela, and M Eppinger-Helft
June 2004, Indian journal of pediatrics,
G Garay, and J Milone, and E Dibar, and S Pavlovsky, and R Kvicala, and F Sackmann Muriel, and D Montres Varela, and M Eppinger-Helft
June 1981, Cancer,
G Garay, and J Milone, and E Dibar, and S Pavlovsky, and R Kvicala, and F Sackmann Muriel, and D Montres Varela, and M Eppinger-Helft
January 1977, Oncology,
G Garay, and J Milone, and E Dibar, and S Pavlovsky, and R Kvicala, and F Sackmann Muriel, and D Montres Varela, and M Eppinger-Helft
September 2023, Urology case reports,
G Garay, and J Milone, and E Dibar, and S Pavlovsky, and R Kvicala, and F Sackmann Muriel, and D Montres Varela, and M Eppinger-Helft
January 2002, Bulletin de la Societe belge d'ophtalmologie,
Copied contents to your clipboard!